A First-in-class highly selective complement 5a receptor antagonist—avacopan
Avacopan is the first highly selective complement 5a receptor antagonist that was approved in China on October 29,2024,for the adjuvant treatment of severe and active antineutrophil cytoplasmic antibody-associated vasculitis(granulomatous polyangitis or microscopic polyangitis)in adults alongside standard treatment containing glucocorticoids.It cannot replace the use of glucocorticoids.Clinical studies have demonstrated the efficacy and safety of avacopan,supporting its use in combination with existing regimens for the treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis.This article reviews its mechanism of action,pharmacokinetics andclinical evaluation,so as to provide reference for its clinical application.
NETL
NSTL
万方数据
